Recent studies (Ozeki and Fukao, 2019; Ricci et al., 2019; Liang et al., 2020) reported that effectiveness of mTOR inhibitor Sirolimus in the treatment of GSD patients; indeed Sirolimus is known to inhibit lymphangiogenesis and is thought to act on lymphatic tissue within lesions regulating production and leakage of lymph (Ozeki and Fukao, 2019). The gene discussed is MTOR; the disease is disorder of glycogen metabolism.